Minoxidil and Methadone Safety Assessment

Key Safety Considerations

Topical minoxidil has minimal systemic absorption and does not affect opioid metabolism or CNS depression risk 1
The concern about methadone safety relates to its inherent cardiac effects and interactions with other CNS depressants, not topical hair loss treatments 2, 3, 4

All patients on methadone require baseline ECG screening to identify QTc prolongation, with interval follow-up based on dose changes 2, 3, 4
Baseline ECG is required for all patients starting methadone, particularly those with elevated QTc, history of palpitations, or syncope 3, 4
Follow-up ECGs should be conducted as early as 2-4 weeks after initiation and when patients reach a certain dose of methadone 3, 4
Monitor for electrolyte abnormalities, as they can impact QTc interval 3, 4

Psychotropics (antidepressants, antipsychotics) that prolong QTc require heightened vigilance when co-prescribed with methadone 3, 4
Macrolide antibiotics (e.g. azithromycin) require caution when used with methadone 3, 4
Certain fluoroquinolones and antimalarials require caution when used with methadone 3, 4
Azole antifungals (e.g. fluconazole) require caution when used with methadone 2, 3
Other CNS depressants (e.g. benzodiazepines, gabapentin, alcohol) increase overdose risk when co-prescribed with methadone 1